Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Yann-Alexandre Vano1, Audrey Simonaggio1, Constance Thibault1

  • 1Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Inserm, UMRS 1138, Centre de recherche des cordeliers, cancer et immunité antitumorale, université Paris-Descartes, Sorbonne-Paris-Cité, F-75006, Paris, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

European urology oncology·2026
Same author

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

European urology oncology·2026
Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026

Immunotherapies, including immune checkpoint inhibitors (ICIs), are revolutionizing clear cell kidney cancer treatment by restoring anti-tumor immunity. Combining ICIs with anti-angiogenic agents or tyrosine kinase inhibitors shows promise for improved outcomes in metastatic renal cell carcinoma.

Area of Science:

  • Oncology
  • Immunology
  • Renal Cell Carcinoma Research

Background:

  • Clear cell kidney cancer (ccRCC) progression is linked to the HIF/VEGF angiogenesis pathway.
  • Anti-angiogenic (AA) agents and mTOR inhibitors have improved metastatic ccRCC (mRCC) patient outcomes.
  • Immune checkpoint inhibitors (ICIs) have revolutionized mRCC management by harnessing anti-tumor immunity.

Purpose of the Study:

  • To review clinical results of immune checkpoint inhibitors in ccRCC.
  • To explore ICI efficacy alone or in combination therapies.
  • To assess ICI use in first-line treatment or post-tyrosine kinase inhibitor (TKI) failure.

Main Methods:

  • Review of clinical trial data for ICI monotherapy and combination therapies in ccRCC.
  • Analysis of treatment outcomes in first-line and refractory settings.
Keywords:
Cancer du reinClear cell renal cellImmune checkpointImmunitéInhibiteurPD-1TKI anti-VEGFRVEGFR-TKIantitumoralecarcinomade checkpointinhibitorà cellules claires

Related Experiment Videos

  • Evaluation of the role of the tumor immune microenvironment (TME) in ccRCC response.

    • Main Results:

    • ICIs demonstrate significant efficacy in ccRCC, highlighting the importance of anti-tumor immunity.
    • The immunosuppressive TME of ccRCC, despite CD8+ T cell infiltration, contributes to ICI effectiveness.
    • Combinations of ICIs with AA agents or TKIs are being investigated for enhanced therapeutic benefit.

    Conclusions:

    • ICIs represent a paradigm shift in ccRCC treatment, particularly for metastatic disease.
    • The rationale for combining ICIs with AA or TKI therapies is strong, warranting further clinical development.
    • Future strategies may involve earlier application of ICIs or novel combination approaches in ccRCC management.